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Patients and Methods: Between 10/04 and 6/06, 24 patients
(pts) with high risk/relapsed/refractory hematologic malignan-
cies have undergone NST using a modiﬁcation of our original
Pt-TBI regimen. The median age was 60 years. The median
number of prior therapies was 2 (range 0-6). Diseases trans-
planted included acute lymphoblastic leukemia (n3), myelo-
dysplastic syndrome (n2), acute myelogenous leukemia (n8),
chronic lymphocytic leukemia (n3), indolent non-Hodgkin’s
lymphoma (n2), and mantle cell lymphoma (n6). Condition-
ing consisted of Pentostatin 4 mg/m2 daily on day -10, -9, and
-8, followed by 200 cGy TBI on day -1. Post-grafting immu-
nosuppression consisted of cyclosporine/mycophenolate
mofetil. Results: Transplantation was performed using mobi-
lized progenitor cells from matched related (n8) or unrelated
(n16) donors. Death prior to 100 days post transplant oc-
curred in 4 unrelated donor transplants. The median nadir
values for hemoglobin, neutrophil count and platelet count were
8.9 g/dl (range 7.6-13.7), 300/mm3 (range 0-1900), and 63/mm3
(range 9-165) respectively. Primary graft failure/autologous re-
covery occurred in one patient with mantle cell lymphoma. The
median values for CD3 cells and WBC at day 28 were 85%
and 90% donor cells respectively. The analogous median values
at day 70 were 85% and 100% respectively. One pt with a
myelproliferative disorder and thalidomide as his only prior
therapy experienced late graft failure despite donor lymphocyte
infusions. The cumulative incidence of grade II-IV acute graft-
versus-host disease was approximately 54% (14% in related
versus 68% in unrelated donors, P0.08). The probability of
extensive chronic graft-versus-host disease in patients surviving
beyond 100 days is 38%. The cumulative incidence of relapse at
one year post transplant is 43%. The one year probabilities of
event-free and overall survival are 41% and 61% respectively.
Conclusions: This modiﬁcation of our original Pt-TBI regi-
men continues to demonstrate fairly minimal regimen related
toxicity, although as expected hematologic toxicity appears to be
more signiﬁcant than with our prior day -21 Pentostatin regi-
men. Graft versus host disease continues to be a major cause of
morbidity/mortality, particularly in unrelated donor trans-
plants. Further studies will concentrate on attempting to de-
crease the incidence of acute and chronic graft versus host
disease through the use of T-cell depletion with in vitro ale-
mtuzumab.
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UMBILICAL CORD BLOOD TRANSPLANTATION FOR ADULT PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
Brunstein, C.1, Setubal, D.1, DeFor, T.1, Weisdorf, D.1, McGlave, P.1,
Miller, J.1, Wagner, J.1 1University of Minnesota Blood and Marrow
Transplant Program, Minneapolis, MN.
Chronic myelogenous leukemia (CML) was primarily treated
with HSCT until imatinib mesilate was shown to be effective
and safe for patients with early chronic phase CML. However,
patients who fail imatinib therapy due to disease progression or
drug intolerance still require HSCT. Umbilical cord blood
(UCB) has been an increasingly used source of hematopoietic
stem cells for transplantation (HSCT) of patients with hemato-
logic malignancies who lack a suitable sibling donor. We report
here on 20 adult patients who underwent UCB transplantation
(UCBT) for Ph CML at the University of Minnesota between
1998 and 2005. Patient received myeloablative (MA, n12) or
nonmyeloablative (NMA, n8) conditioning, The median age
was 46 y (r: 18-58), 12 (60%) were male, and median weight was
78 kg (r: 57-103), and 13 (65%) were CMV positive. The MA
conditioning was Bu/Cy (n2) Cy/TBI  ATG (n4), or Cy/
Fludarabine(Flu)/TBI (n6). The NMA conditioning was Bu/
Flu/TBI (n2) or Cy/Flu/TBI ATG (n6). Posttransplanta-
tion immunosuppression was CsA alone (n1), CsA/
methylprednisolone(MP) (n5), or CsA/MMF (n14). Eleven
patients (55%) receive a double UCB graft. The highest HLA
disparity of UCB units was 4/6 (n13), 5/6 (n5), and 6/6
(n2). Six patients (30%) were in ﬁrst chronic phase (CP1) and
14 (70%) were in accelerated phase (AP) CML. The median
TNC dose infused was 2.9  107/kg (r:1.2-5.3) and median
CD34 dose infused was 4.8  105/kg (r: 0.7-12.7). The median
time from diagnosis to transplant was 24.5 months (r: 6.7-
118.8), and the median follow-up of surviving patients was 2.9
yrs (r: 0.7-.7.0). There were no failures of neutrophil engraft-
ment. In the MA setting median time to neutrophil engraftment
was 21d (r:13-33), grade II-IV acute GVHD was 58% (95%CI,
28-88%), 1-yr transplant related mortality (TRM) 41%
(95%CI, 13-69), 2-yr relapse rate 10% (95%CI, 0-26), and
overall survival 58% (95%CI, 30-86). In the NMA setting me-
dian time to neutrophil engraftment was 13d (r:5-32), grade
II-IV acute GVHD was 63% (95%CI, 28-98%), 1-yr transplant
related mortality (TRM) 38% (95%CI, 6-70), 2-yr relapse rate
13% (95%CI, 0-34), and overall survival 50% (95%CI, 15-85).
There was no statistically signiﬁcant difference between MA and
NMA conditioning regimens on all outcomes. In this report we
show that UCB appears to be a safe and effective HSC for
transplantation of patients with CML.
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FLUDARABINE/FULL DOSE I.V. BUSULFAN CONDITIONING REGIMEN IN
ALLOGENEIC PBSC TRANSPLANTATION FOR HIGH RISK PATIENTS
Chunduri, S.1, Dobogai, L.C.1, Peace, D.1, Saunthararajah, Y.1,
Quigley, J.1, Chen, Y.-H.1, Boccuni, P.1, Hoffman, R.1, Mahmud, N.1,
Beri, R.1, Hurter, E.1, Rondelli, D.1 1Section of Hematology/Oncology,
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Fludarabine/ full dose busulfan (FluBu) conditioning regimen
causes moderate extrahematologic toxicity and low rates of acute
graft-versus-host disease (GVHD) in allogeneic hematopoietic
stem cell transplantation (HSCT).
In this study we utilized this regimen in 21 adult patients with
hematologic malignancies, including 15 patients (71%) at high risk
of relapse (8 acute leukemia in relapse, 3 NHL in relapse, 1 NHL
in CR2, 1 myeloﬁbrosis in transformation, 2 CML-AP resistant to
imatinib) and 6 patients at standard risk (3 AML in CR1, 2
CML-CP resistant to imatinib, 1 MDS). All patients were prepared
with ﬂudarabine (30 or 40 mg/m2/day) for 4 days from d-9 to d-6
and i.v. busulfan (3.2 mg/kg/day) for 4 days from d-5 to d-2, and
received an HLA matched related (n14) or unrelated (n7)
peripheral blood stem cell (PBSC) transplant. Mean number of
CD34 cells infused was 7.34.0  106/kg. Thymoglobulin was
added to the preparative regimen on d -3 to d-1 in 9 patients,
including those receiving an unrelated HSCT. Acute GVHD pro-
phylaxis included standard tacrolimus and methotrexate on d1, d3,
d6 and d11. All patients fully engrafted but one ALL patient
transplanted in relapse who recovered with leukemic blasts. Me-
dian times to ANC 0.5109/L and platelet 20109/L were 15d
(range: 18-24) and 13d (range: 0-24), respectively. Acute GVHD
grade II-IV was observed in 24% of the patients (grade III-IV
18%) and chronic GVHD in 9 of 14 evaluable patients (64%). Of
21 patients, 8 died in full relapse with bacterial or fungal infection
and 2 for acute GVHD grade III and fungal infection. Median time
to relapse after HSCT was 72d (range: 18-328). At a median
follow-up of 447 d (range: 120-1196) for patients who are alive, the
overall survival (OS) and event-free survival (EFS) are 52% and
48%, respectively. In the group at high risk the OS and EFS are
both 33% at 447 d median follow-up (range: 147-834).
FluBu conditioning regimen, besides causing low transplant-
related morbidity and mortality, is also effective in high risk pa-
tients receiving an allogeneic PBSC transplant from related or
unrelated donors.
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HAPLOIDENTICAL NON-MYELOABLATIVE HEMATOPOIETIC TRANS-
PLANT WITH SIROLIMUS BASED IMMUNOSUPPRESSION YIELDS RELI-
ABLE ENGRAFTMENT AND MAY RESULT IN LONG TERM SURVIVAL
Claxton, D.F.1, Creme, L.1, Ehmann, W.C.1, Rybka, W.B.1 1Penn
State Cancer Institute, Hershey, PA.
Timely availability of matched donors limits allo-hematopoi-
etic transplant (HCT) options for many otherwise suitable pa-
tients. We have explored sirolimus (rapamycin) based immuno-
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